Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y5S2
UPID:
MRCKB_HUMAN
Alternative names:
CDC42-binding protein kinase beta; DMPK-like beta; Myotonic dystrophy kinase-related CDC42-binding kinase beta
Alternative UPACC:
Q9Y5S2; A9JR72; Q2L7A5; Q86TJ1; Q9ULU5
Background:
Serine/threonine-protein kinase MRCK beta, also known as CDC42-binding protein kinase beta, plays a pivotal role in cytoskeleton reorganization and cell migration. It achieves this through phosphorylation of key proteins such as PPP1R12C and MYL9/MLC2, crucial for actin cytoskeletal reorganization. Additionally, it collaborates with MYO18A and LURAP1 to modulate lamellar actomyosin retrograde flow, essential for cell protrusion and migration.
Therapeutic significance:
The protein's involvement in Chilton-Okur-Chung neurodevelopmental syndrome, characterized by developmental delay and intellectual disability, underscores its therapeutic significance. Understanding the role of Serine/threonine-protein kinase MRCK beta could open doors to potential therapeutic strategies for this and related disorders.